Microneedle delivery of autoantigen for immunotherapy in type 1 diabetes

Zhao, Xin, Birchall, James C. ORCID: https://orcid.org/0000-0001-8521-6924, Coulman, Sion A. ORCID: https://orcid.org/0000-0002-1277-7584, Tatovic, Danijela ORCID: https://orcid.org/0000-0002-3879-2686, Singh, Ravinder K., Wen, Li, Wong, F. Susan ORCID: https://orcid.org/0000-0002-2812-8845, Dayan, Colin M. ORCID: https://orcid.org/0000-0002-6557-3462 and Hanna, Stephanie J. 2016. Microneedle delivery of autoantigen for immunotherapy in type 1 diabetes. Journal of Controlled Release 223 , pp. 178-187. 10.1016/j.jconrel.2015.12.040

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (1MB) | Preview

Abstract

Antigen specific immunotherapy mediated via the sustained generation of regulatory T cells arguably represents the ideal therapeutic approach to preventing beta cell destruction in type 1 diabetes. However, there is a need to enhance the efficacy of this approach to achieve disease modification in man. Previous studies suggest that prolonged expression of self-antigen in skin in a non-inflammatory context is beneficial for tolerance induction. We therefore sought to develop a dry-coated microneedle (MN) delivery system and combine it with topical steroid to minimise local inflammation and promote prolonged antigen presentation in the skin. Here we show that a combination of surface-modified MNs coated with appropriate solvent systems can deliver therapeutically relevant quantities of peptide to mouse and human skin even with hydrophobic peptides. Compared to conventional “wet” intradermal (ID) administration, “dry” peptide delivered via MNs was retained for longer in the skin and whilst topical hydration of the skin with vehicle or steroid accelerated loss of ID-delivered peptide from the skin, MN delivery of peptide was unaffected. Furthermore, MN delivery resulted in enhanced presentation of antigen to T cells in skin draining lymph nodes (LNs) both 3 and 10 days after administration. Repeated administration of islet antigen peptide via MN was effective at reducing antigen-specific T cell proliferation in the pancreatic LN, although topical steroid therapy did not enhance this. Taken together, these data show auto-antigenic peptide delivery into skin using coated MNs results in prolonged retention and enhanced antigen presentation compared to conventional ID delivery and this approach may have potential in individuals identified as being at a high risk of developing type 1 diabetes and other autoimmune diseases.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Pharmacy Medicine
Subjects:	R Medicine > R Medicine (General)
Additional Information:	This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license
Publisher:	Elsevier
ISSN:	0168-3659
Date of First Compliant Deposit:	30 March 2016
Date of Acceptance:	23 December 2015
Last Modified:	10 Feb 2024 02:12
URI:	https://orca.cardiff.ac.uk/id/eprint/84568

Citation Data

Cited 27 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item